A new blood test could help doctors detect pancreatic cancer earlier, potentially improving survival rates for one of the deadliest cancers.

Global genital herpes treatment market will reach $5,051.8 million by 2032, growing by 4.7% annually over 2022-2032, driven by the rising prevalence of sexually transmitted diseases, changing ...

Request To Download Free Sample of This Strategic Report @ Highlighted with 32 tables and 44 figures, this 110-page report ?Asia Pacific Genital Herpes Treatment Market 2022-2032 by Virus Type (HSV-1 ...

The Target-MRD blood test uses a combination of tumor-informed and tumor-agnostic molecular features for personalized, accurate and more effective monitoring of molecular residual disease.

California-based space company Rocket Lab will launch more hypersonic ... of the Under Secretary of Defense for Research and Engineering (OUSD (R&E) Test Resource Management Center (TRMC), an ...

But this is declining by about 2% each year while new genital infections that result from HSV-1 are rising. Genital herpes causes a substantial disease ... is now so common, testing is not usually ...

While LRRK2 GTPase is a crucial target for Parkinson's Disease research, it is difficult to selectively modulate GTPases with drugs. Further, one part of the GTPase domain, the COR domain ...

A molecular diagnostics start-up founded by former IISc professor and biotech entrepreneur Vijay Chandru has recently opened a laboratory in Bengaluru for developing diagnostics for rare diseases like ...

But the ramifications of the research could go even further, applying to a range of similar diseases that affect thousands of Australians such as Fragile X syndrome and Friedreich's ataxia.

Scientists are unraveling the mystery of what triggers Huntington’s disease, a devastating and ... any problems until later in life. New research shows that the mutation is, surprisingly ...